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Abstract
Gastric variceal bleeding is a common problem in patients with cirrhosis and is associated with
increased morbidity and mortality. Management is complex and includes pharmacotherapy,
endoscopic therapy, and shunt placement. Recent studies indicate that endoscopic therapy with
tissue adhesives has similar hemostasis rates and outcomes in terms of mortality as shunt placement
but has a lower complication rate and therefore could be considered the first line therapy for acute
bleeding and secondary prophylaxis of gastric varices.
Introduction and context
Varicealbleedingisthemostcommonlethalcomplication
of cirrhosis, with a mortality rate of 20% [1,2]. Gastro-
esophageal varices (GOVs) are present in 50% of
cirrhotics, and approximately 25% of patients with portal
hypertension have gastric varices [3,4]. Gastric varices are
commonlyclassifiedasGOVs(gastricvaricesincontinuity
with esophageal varices) and isolated gastric varices
(IGVs). These are further divided into GOV1 (GOVs
alongthelessercurveofthestomach),GOV2(GOVsalong
thefundus),IGV1(IGVsinthefundus),andIGV2(IGVsin
the gastric body, pylorus, or antrum). Although the
prevalence and risk of bleeding of gastric varices are
lower than those of esophageal varices, gastric variceal
bleeding tends to be more severe, requires more transfu-
sions, and is associated with higher mortality (~45%) [5].
Gastric varices tend to be larger and more tortuous
compared with esophageal varices, characteristics that,
combined with their anatomical location (particularly
fundic varices), make endoscopic management more
challenging. Current management strategies for gastric
varices include pharmacotherapy (b-blockers and vasoac-
tiveagents),endoscopictherapy(bandligation,thrombin,
and tissue adhesives), transjugular intrahepatic portosys-
temic shunt (TIPS) placement, and surgical intervention.
Large, well-conducted trials comparing these therapeutic
modalities are lacking. Therefore, recommendations for
management of gastric varices are based on recent
prospective and retrospective studies, expert consensus
opinion, and experience with esophageal varices.
Recent advances
Primary prophylaxis
The pathophysiology of gastric varices is not as well
understood as that of esophageal varices; however, the
former are mostly seen in patients with cirrhotic portal
hypertension. IGV1 gastric varices are an exception and
frequently result from isolated splenic vein thromboses.
Therefore, the treatment of choice for IGV1 varices is
splenectomy. No studies to evaluate pharmacologic
therapy or endoscopic therapy for primary prophylaxis
of gastric varices have been performed, and recommen-
dations are based primarily on the guidelines for
managing esophageal varices. Large gastric varices with
red color signs, especially in patients with advanced liver
disease (Child's class C), are most likely to bleed [4,6].
These patients may be treated with non-selective
b-blockers to prevent variceal hemorrhage. Endoscopic
treatment or TIPS is not currently recommended for
primary prophylaxis of gastric varices.
Treatment of acute bleeding and secondary prophylaxis
EndoscopictherapyandTIPSarebothconsideredfirst-line
treatments for gastric variceal bleeding; however, current
Page 1 of 4
(page number not for citation purposes)
Published: 12 April 2010
© 2010 Medicine Reports Ltd
for non-commercial purposes provided the original work is properly cited. You may not use this work for commercial purposes.
This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial License
(http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits unrestricted use, distribution, and reproduction in any medium,guidelines favor endoscopy as the preferred initial inter-
vention [7,8]. Endoscopic therapeutic options for gastric
variceal bleeding include band ligation, tissue adhesives,
thrombin, and sclerotherapy. The greatest evidence exists
for tissue adhesives such as cyanoacrylate (N-butyl-2-
cyanoacrylate, ‘glue’); however, cyanoacrylate is not
routinely available in the US. Cyanoacrylate undergoes
rapid polymerization on contact with living tissues and
obliteration of varices occurs when the injected cyanoa-
crylate adhesive hardens on contact with blood. The
mucosa overlying the varix eventually sloughs and the
polymer is extruded. Two randomized controlled trials
have compared cyanoacrylate injection with variceal band
ligation, showing mixed results for initial hemostasis but
reduced rebleeding rates with cyanoacrylate (22% versus
44%and31%versus54%)[9,10].Therewasnodifference
in mortality rates. Another study compared cyanoacrylate
injection with sclerotherapy and found better control of
initial hemostasis as well as lower rebleeding rates with
cyanoacrylate [11]. Meticulous adherence to technique is
crucial when using tissue adhesives to prevent irreversible
damagetoendoscopescausedbypolymerization.Arecent
study reported the use of endoscopic ultrasound to guide
injection of feeding veins with excellent results; however,
the riskofdamagingexpensive equipment may prevent its
widespread usage [12]. Complications of tissue adhesives
include embolization, with case reports of portal vein
embolization, coronary emboli, splenic infarction, pul-
monary emboli, and cerebral stroke [13-16].
Thrombin is a promising agent that does not carry the
risk of embolization and damage to equipment. A recent
study using bovine thrombin to control gastric variceal
bleeding demonstrated a hemostasis rate of 92% and no
episodes of rebleeding [17]. Several other studies with
thrombin have shown promising results [17-19]. How-
ever, controlled trials comparing thrombin with other
agents are required before it is universally accepted.
The role of TIPS in the management of gastric varices
alone or in comparison with esophageal varices has been
investigated in multiple studies. Chau et al. [20] reported
a 96% initial hemostasis rate and 29% rebleeding rate
with TIPS in patients with fundal varices, and these were
Figure 1. Algorithm for management of gastric varices
h/o, history of; TIPS, transjugular intrahepatic portosystemic shunt.
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In another retrospective series comparing TIPS in 40
cirrhotics with gastric variceal bleeding and 232 patients
with esophageal variceal bleeding, the rates of rebleeding
were similar (20% versus 15%) [21].
Clearly, with hemostasis rates over 90%, tissue adhesives
and TIPS are both highly effective management options
for gastric variceal bleeding. Very few studies have
compared the two therapies. Lo et al. [22] carried out a
randomized controlled trial comparing TIPS (n = 35)
and cyanoacrylate glue (n = 37) for secondary prophy-
laxis of gastric variceal bleeding. There was no difference
in survival or complication rates. However, the rebleed-
ing rate was significantly higher in the cyanoacrylate arm
compared with the TIPS arm (38% versus 11%). In a
UK-based retrospective study, the two therapies were
equally effective for initial hemostasis but patients with
TIPS had a lower rebleeding rate (20% versus 35%) [23].
However, TIPS was considerably more expensive than
cyanoacrylate therapy. Finally, in a recent retrospective
study comparing TIPS (n = 44) and cyanoacrylate
therapy (n = 61) for gastric variceal bleeding, rebleeding
rates and mortality rates were similar between the two
groups. However, the TIPS group had increased morbid-
ity requiring hospitalization and had a higher incidence
of encephalopathy (11 versus 1) [24].
Implications for clinical practice
The initial steps in the management of gastric variceal
bleeding are similar to esophageal varices and include
attention to airway and obtaining intravenous access with
prompthemodynamic resuscitation, institution ofvasoac-
tive medications (somatostatin analogues, octreotide,
vasopressin, and terlipressin) to reduce portal pressure
by splanchnic vasoconstriction and prophylactic antibio-
tics followed by diagnostic and potentially therapeutic
upper endoscopy (Figure 1). The next step in the manage-
ment may be endoscopic injection of tissue adhesives or
TIPS placement. With a lower complication rate, compar-
able hemostasis and survival rates, and lower cost,
endoscopic therapy with tissue adhesives is likely to be
the treatment of choice for acute bleeding and secondary
prophylaxis in most patients.Onthe other hand, TIPS will
remainanimportantsecond-linemodalityinpatientswho
fail endoscopic therapy. However, additional controlled
studies are needed before valid conclusions can be made,
and individual patient characteristics must be considered
in management decisions. Primary prophylaxis may be
instituted with b-blockers in patients with large varices
with red color signs and advanced liver disease. Further
research on management of acute bleeding, primary
prophylaxis, and comparisons between tissue adhesives
and thrombin would be welcome.
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